Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rani Therapeutics Holdings

1.06
-0.0600-5.36%
Pre-market: 1.060.00000.00%08:04 EDT
Volume:214.25K
Turnover:240.93K
Market Cap:35.31M
PE:-1.01
High:1.18
Open:1.15
Low:1.05
Close:1.12
Loading ...

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
26 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
17 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Rani Therapeutics Holdings (RANI)

TIPRANKS
·
02 Mar

RANI: Impressive Bioavailability for RT-116

Zacks Small Cap Research
·
18 Feb

Rani Zim Announces Sale of Controlling Shareholder’s Stake

TIPRANKS
·
17 Feb

Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week

Simply Wall St.
·
15 Feb

Rani Zim’s Annual Report Emphasizes Informational Purpose

TIPRANKS
·
11 Feb

Rani Zim Completes Private Placement of Debentures

TIPRANKS
·
10 Feb

Rani Zim Shopping Centers Announces Changes in Securities Register

TIPRANKS
·
10 Feb

US Stocks Likely To Open Higher Ahead Of Amazon's Earnings: 'Buy The Dip' Mentality Remains Prevalent, Says Analyst

Benzinga
·
06 Feb

Rani Therapeutics Discloses Progress in Oral Obesity Treatment; Shares Surge Premarket

MT Newswires Live
·
06 Feb

Rani Therapeutics announces data from semaglutide via RaniPill capsule trial

TIPRANKS
·
06 Feb

BRIEF-Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery Of Semaglutide Via Ranipill HC

Reuters
·
06 Feb

Rani Therapeutics Holdings Inc - Phase 1 Study for Rt-114 Expected to Initiate in 2025

THOMSON REUTERS
·
06 Feb

Rani Therapeutics Holdings Inc - Rt-116 Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
06 Feb

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via Ranipill® Hc

THOMSON REUTERS
·
06 Feb

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

GlobeNewswire
·
06 Feb

RANI: Third Quarter Update

Zacks Small Cap Research
·
20 Nov 2024

Rani Therapeutics Holdings: Buy Rating Backed by Strong Financial Outlook and Strategic Focus on RT-114 Program

TIPRANKS
·
19 Nov 2024